About GlyCardial Diagnostics
GlyCardial Diagnostics is a company based in Barcelona (Spain) founded in 2017 by Judit Cubedo, Gemma Vilahur, Teresa Padro, and Lina Badimon.. GlyCardial Diagnostics has raised $2.8 million across 7 funding rounds from investors including EIT Health, Ship2B and European Union. GlyCardial Diagnostics offers products and services including iSCOR. GlyCardial Diagnostics operates in a competitive market with competitors including Conavi, Acarix, Ionetix, Infraredx and Cleveland HeartLab, among others.
- Headquarter Barcelona, Spain
- Founders Judit Cubedo, Gemma Vilahur, Teresa Padro, Lina Badimon
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.8 M (USD)
in 7 rounds
-
Latest Funding Round
$56.62 K (USD), Grant
Dec 31, 2021
-
Investors
EIT Health
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GlyCardial Diagnostics
GlyCardial Diagnostics offers a comprehensive portfolio of products and services, including iSCOR. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Biomarker for early detection of cardiac ischemia via blood analysis
Funding Insights of GlyCardial Diagnostics
GlyCardial Diagnostics has successfully raised a total of $2.8M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $56.62 thousand completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Grant — $56,620
-
First Round
First Round
(13 Nov 2017)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Grant - GlyCardial Diagnostics | Valuation |
investors |
|
| Mar, 2019 | Amount | Grant - GlyCardial Diagnostics | Valuation |
investors |
|
| Sep, 2018 | Amount | Grant - GlyCardial Diagnostics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GlyCardial Diagnostics
GlyCardial Diagnostics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include EIT Health, Ship2B and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Healthcare startups are accelerated and incubated through specialized programs.
|
Founded Year | Domain | Location | |
|
Social impact investments are facilitated through four acceleration programs.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GlyCardial Diagnostics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - GlyCardial Diagnostics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Glycardial Diagnostics Comparisons
Competitors of GlyCardial Diagnostics
GlyCardial Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Conavi, Acarix, Ionetix, Infraredx and Cleveland HeartLab, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Catheter-based ultrasound systems for cardiac imaging are developed.
|
|
| domain | founded_year | HQ Location |
A screening device for acoustic coronary artery diseases is provided.
|
|
| domain | founded_year | HQ Location |
Superconducting cyclotrons for PET radioisotopes are developed by Ionetix.
|
|
| domain | founded_year | HQ Location |
Coronary imaging and plaque detection system
|
|
| domain | founded_year | HQ Location |
Cardiovascular biomarkers are utilized for disease prevention and management.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostic solution for vulnerable plaque in the coronary arteries
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about GlyCardial Diagnostics
When was GlyCardial Diagnostics founded?
GlyCardial Diagnostics was founded in 2017.
Where is GlyCardial Diagnostics located?
GlyCardial Diagnostics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Who is the current CEO of GlyCardial Diagnostics?
Judit Cubedo is the current CEO of GlyCardial Diagnostics. They have also founded this company.
Is GlyCardial Diagnostics a funded company?
GlyCardial Diagnostics is a funded company, having raised a total of $2.8M across 7 funding rounds to date. The company's 1st funding round was a Grant of $58.01K, raised on Nov 13, 2017.
What does GlyCardial Diagnostics do?
GlyCardial Diagnostics was established in 2017 as a spin-off from the Catalan Institute of Cardiovascular Sciences in Barcelona, Spain. Focus is placed on commercializing Apo J-Glyc as a blood-based biomarker for early detection of myocardial ischemia and prediction of patient outcomes post-event. An in vitro diagnostic device is being developed to utilize this biomarker within the cardiovascular diagnostics sector. Operations center on biomarker validation and device prototyping for clinical applications.
Who are the top competitors of GlyCardial Diagnostics?
What products or services does GlyCardial Diagnostics offer?
GlyCardial Diagnostics offers iSCOR.
Who are GlyCardial Diagnostics's investors?
GlyCardial Diagnostics has 6 investors. Key investors include EIT Health, Ship2B, European Union, EIC Fund, and Caixa Capital Risc.